How to buy Evotec stock (Evotec SE)

Evotec is a drug manufacturers - specialty & generic business based in the US. Evotec shares (EVO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $4.54 – an increase of 1.57% over the previous week. Evotec employs 5,007 staff and has a trailing 12-month revenue of around $777.1 million.

Our top picks for where to buy Evotec SE ADR stock

Buy Evotec stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Evotec stock price (NASDAQ: EVO)

Use our graph to track the performance of EVO stocks over time.

Evotec shares at a glance

• Key figures

Information last updated 2024-12-26.

Latest market close	$4.54
52-week range	$2.85 - $11.91
50-day moving average more info button	$4.36
200-day moving average more info button	$4.77
Wall St. target price	$6.23
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.50

Is it a good time to buy Evotec stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Evotec price performance over time

Historical closes compared with the close of $4.88 from 2024-12-26

1 week (2024-12-20)	9.17%
1 month (2024-11-27)	1.04%
3 months (2024-09-27)	36.69%
6 months (2024-06-28)	1.67%

1 year (2023-12-28)	-58.78%
2 years (2022-12-28)	-37.44%
3 years (2021-12-28)	23.55
5 years (2019-12-27)	12.875

Is Evotec stock undervalued or overvalued?

Valuing Evotec stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Evotec's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Evotec's EBITDA

Evotec's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $15.9 million.

The EBITDA is a measure of a Evotec's overall financial performance and is widely used to measure a its profitability.

To put Evotec's EBITDA into context you can compare it against that of similar companies.

• Pfizer (PFE.US): USD$18.4 billion
• Moderna (MRNA.US): USD$-2361999872
• Johnson-and-Johnson (JNJ.US): USD$30.1 billion

Evotec financials

Revenue TTM	$777.1 million
Gross profit TTM	$151.5 million
Return on assets TTM	-1.77%
Return on equity TTM	-16.25%
Profit margin	-22.05%
Book value	$5.46
Market Capitalization more info button	$1.8 billion

TTM: trailing 12 months

Evotec share dividends

We're not expecting Evotec to pay a dividend over the next 12 months.

You may also wish to consider:

• Pfizer (PFE.US) (6.53% forward annual dividend yield)
• Johnson-and-Johnson (JNJ.US) (3.43% forward annual dividend yield)

Have Evotec's shares ever split?

Evotec's shares were split on a 4:1 basis on 19 October 2021 . So if you had owned 1 share the day before before the split, the next day you'd have owned 4 shares. This wouldn't directly have changed the overall worth of your Evotec shares – just the quantity. However, indirectly, the new 75% lower share price could have impacted the market appetite for Evotec shares which in turn could have impacted Evotec's share price.

Evotec share price volatility

Over the last 12 months, Evotec's shares have ranged in value from as little as $2.85 up to $11.91. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Evotec's is 0.984. This would suggest that Evotec's shares are less volatile than average (for this exchange).

To put Evotec's beta into context you can compare it against those of similar companies.

• Pfizer (PFE.US): 0.615
• Moderna (MRNA.US): 1.69
• Johnson-and-Johnson (JNJ.US): 0.518

Evotec overview

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc. ; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany. .

Frequently asked questions

null
What percentage of Evotec is owned by institutions?
Currently 2.369% of Evotec shares are held by institutions. How many people work for Evotec?
Latest data suggests 5,007 work at Evotec. When does the fiscal year end for Evotec?
Evotec's fiscal year ends in December. Where is Evotec based?
Evotec's address is: Essener Bogen 7, Hamburg, Germany, 22419 What is Evotec's ISIN number?
Evotec's international securities identification number is: US30050E1055